Spyre Therapeutics Inc SYRE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SYRE is a good fit for your portfolio.
News
-
Spyre Therapeutics Announces Grants of Inducement Awards
-
Spyre Therapeutics Announces $180 Million Private Placement
-
Spyre Therapeutics Announces Grants of Inducement Awards
-
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-
Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference
-
Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation
-
Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors
-
Spyre Therapeutics Announces Grants of Inducement Awards
Trading Information
- Previous Close Price
- $32.47
- Day Range
- $32.50–34.31
- 52-Week Range
- $2.66–47.97
- Bid/Ask
- $33.51 / $33.56
- Market Cap
- $1.23 Bil
- Volume/Avg
- 225,967 / 505,227
Key Statistics
- Price/Earnings (Normalized)
- 12.77
- Price/Sales
- 256.81
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 30
- Website
- https://www.spyre.com
Valuation
|
Metric
|
SYRE
|
|---|---|
Price/Earnings (Normalized) | 12.77 |
Price/Book Value | — |
Price/Sales | 256.81 |
Price/Cash Flow | — |
Price/Earnings
SYRE
Financial Strength
|
Metric
|
SYRE
|
|---|---|
Quick Ratio | 10.61 |
Current Ratio | 10.68 |
Interest Coverage | — |
Quick Ratio
SYRE
Profitability
|
Metric
|
SYRE
|
|---|---|
Return on Assets (Normalized) | 9.72% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
SYRE
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dggtwnhjkq | Mnltv | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bttzwyvx | Btcrjmh | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Gchftwbq | Lfsgrjz | $97.8 Bil | |
MRNA
| Moderna Inc | Wvdfmnfyf | Vwgwf | $41.3 Bil | |
ARGX
| argenx SE ADR | Pjxpmst | Cxtlz | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Sznczygq | Jzd | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gcwsntwyw | Bpnfz | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dywssgjd | Dgfskl | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bksvdxszh | Xblzgn | $12.5 Bil | |
INCY
| Incyte Corp | Pwfyjcqx | Xpbjyhf | $11.6 Bil |